US Code
Part A— Drugs and Devices
§ 360l. Postmarket surveillance

(a) Postmarket surveillance(1) In general(A) ConductThe Secretary may by order, at the time of approval or clearance of a device or at any time thereafter, require a manufacturer to conduct postmarket surveillance for any device of the manufacturer that is a class II or class III device—(i) the failure of which would be reasonably likely to have serious adverse health consequences;
(ii) that is expected to have significant use in pediatric populations; or
(iii) that is intended to be—(I) implanted in the human body for more than 1 year; or
(II) a life-sustaining or life-supporting device used outside a device user facility.
(B) ConditionThe Secretary may order a postmarket surveillance under subparagraph (A) as a condition to approval or clearance of a device described in subparagraph (A)(ii).
(2) Rule of constructionThe provisions of paragraph (1) shall have no effect on authorities otherwise provided under the 11 So in original. Probably should be “this”. chapter or regulations issued under this chapter.
(b) Surveillance approval(1) In generalEach manufacturer required to conduct a surveillance of a device shall, within 30 days of receiving an order from the Secretary prescribing that the manufacturer is required under this section to conduct such surveillance, submit, for the approval of the Secretary, a plan for the required surveillance. The Secretary, within 60 days of the receipt of such plan, shall determine if the person designated to conduct the surveillance has appropriate qualifications and experience to undertake such surveillance and if the plan will result in the collection of useful data that can reveal unforeseen adverse events or other information necessary to protect the public health. The manufacturer shall commence surveillance under this section not later than 15 months after the day on which the Secretary issues an order under this section. Except as provided in paragraph (2), the Secretary, in consultation with the manufacturer, may by order require a prospective surveillance period of up to 36 months. Except as provided in paragraph (2), any determination by the Secretary that a longer period is necessary shall be made by mutual agreement between the Secretary and the manufacturer or, if no agreement can be reached, after the completion of a dispute resolution process as described in section 360bbb–1 of this title.
(2) Longer surveillance for pediatric devicesThe Secretary may by order require a prospective surveillance period of more than 36 months with respect to a device that is expected to have significant use in pediatric populations if such period of more than 36 months is necessary in order to assess the impact of the device on growth and development, or the effects of growth, development, activity level, or other factors on the safety or efficacy of the device.
(c) Dispute resolutionA manufacturer may request review under section 360bbb–1 of this title of any order or condition requiring postmarket surveillance under this section. During the pendency of such review, the device subject to such a postmarket surveillance order or condition shall not, because of noncompliance with such order or condition, be deemed in violation of section 331(q)(1)(C) of this title, adulterated under section 351(f)(1) of this title, misbranded under section 352(t)(3) of this title, or in violation of, as applicable, section 360(k) of this title or section 360e of this title, unless deemed necessary to protect the public health.

Structure US Code

US Code

Title 21— FOOD AND DRUGS

CHAPTER 9— FEDERAL FOOD, DRUG, AND COSMETIC ACT

SUBCHAPTER V— DRUGS AND DEVICES

Part A— Drugs and Devices

§ 351. Adulterated drugs and devices

§ 352. Misbranded drugs and devices

§ 353. Exemptions and consideration for certain drugs, devices, and biological products

§ 353a. Pharmacy compounding

§ 353a–1. Enhanced communication

§ 353b. Outsourcing facilities

§ 353c. Prereview of television advertisements

§ 353d. Process to update labeling for certain generic drugs

§ 354. Veterinary feed directive drugs

§ 355. New drugs

§ 355–1. Risk evaluation and mitigation strategies

§ 355–2. Actions for delays of generic drugs and biosimilar biological products

§ 355a. Pediatric studies of drugs

§ 355b. Adverse-event reporting

§ 355c. Research into pediatric uses for drugs and biological products

§ 355c–1. Report

§ 355d. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers

§ 355e. Pharmaceutical security

§ 355f. Extension of exclusivity period for new qualified infectious disease products

§ 355g. Utilizing real world evidence

§ 355h. Regulation of certain nonprescription drugs that are marketed without an approved drug application

§ 356. Expedited approval of drugs for serious or life-threatening diseases or conditions

§ 356–1. Accelerated approval of priority countermeasures

§ 356–2. Accelerated approval Council

§ 356a. Manufacturing changes

§ 356b. Reports of postmarketing studies

§ 356c. Discontinuance or interruption in the production of life-saving drugs

§ 356c–1. Annual reporting on drug shortages

§ 356d. Coordination; task force and strategic plan

§ 356e. Drug shortage list

§ 356f. Hospital repackaging of drugs in shortage

§ 356g. Standards for regenerative medicine and regenerative advanced therapies

§ 356h. Competitive generic therapies

§ 356i. Prompt reports of marketing status

§ 356j. Discontinuance or interruption in the production of medical devices

§ 356k. Platform technologies

§ 356l. Advanced manufacturing technologies designation program

§ 357. Qualification of drug development tools

§ 358. Authority to designate official names

§ 359. Nonapplicability of subchapter to cosmetics

§ 360. Registration of producers of drugs or devices

§ 360a. Clinical trial guidance for antibiotic drugs

§ 360a–1. Clinical trials

§ 360a–2. Susceptibility test interpretive criteria for microorganisms

§ 360b. New animal drugs

§ 360b–1. Priority zoonotic animal drugs

§ 360c. Classification of devices intended for human use

§ 360c–1. Reporting

§ 360d. Performance standards

§ 360e. Premarket approval

§ 360e–1. Pediatric uses of devices

§ 360e–3. Breakthrough devices

§ 360e–4. Predetermined change control plans for devices

§ 360f. Banned devices

§ 360g. Judicial review

§ 360g–1. Agency documentation and review of significant decisions regarding devices

§ 360g–2. Third party data transparency

§ 360h. Notification and other remedies

§ 360h–1. Program to improve the device recall system

§ 360i. Records and reports on devices

§ 360j. General provisions respecting control of devices intended for human use

§ 360k. State and local requirements respecting devices

§ 360l. Postmarket surveillance

§ 360m. Accredited persons

§ 360n. Priority review to encourage treatments for tropical diseases

§ 360n–1. Priority review for qualified infectious disease products

§ 360n–2. Ensuring cybersecurity of devices